CDK7-IN-6

• Description :

  CDK7-IN-6 is a potent and selective cyclin-dependent kinase (CDK7) inhibitor (IC50≤100 nM), extracted from patent WO2019197549 A1, compound 210. CDK7-IN-6 is > 200-fold selective for CDK7 over CDK1, CDK2, and CDK5. CDK7-IN-6 can be used for the research of cancer[1].

• UNSPSC :

  12352005

• Target :

  CDK

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/cdk7-in-6.html

• Solubility :

  10 mM in DMSO

• Smiles :

  ClC1=CC=CC(N2N=C(C(C)(C)O)C=C2)=C1CNC3=NC(N4CCC(CC4)N)=NC5=C(C(C)C)C=NN35

• Molecular Formula :

  C26H34ClN9O

• Molecular Weight :

  524.06

• References & Citations :

  [1]Kiyean NAM, et al.Preparation of pyrazolotriazine and/or pyrazolopyrimidine derivatives as selective inhibitor of cyclin dependent kinase. WO2019197549 A1.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  CDK7

• CAS Number :

  [2378710-04-2]